Transaction DateRecipientSharesTypePriceValue
6th October 2020Partners L P/Il Bvf25,107Open or private purchase$5.04$126,413.75
6th October 2020Partners L P/Il Bvf157,782Open or private purchase$5.04$794,432.37
6th October 2020Partners L P/Il Bvf162,352Open or private purchase$5.04$817,442.32
5th October 2020Ventures Iv, L.P. 5 Am175,000Open or private sale$25.30$4,427,500.00
23rd September 2020Partners L P/Il Bvf7,201Open or private purchase$18.20$131,056.76
23rd September 2020Partners L P/Il Bvf9,888Open or private purchase$18.20$179,959.62
22nd September 2020Partners L P/Il Bvf32Open or private purchase$3.80$121.56
22nd September 2020Partners L P/Il Bvf4,991Open or private purchase$18.45$92,062.49
22nd September 2020Partners L P/Il Bvf6,960Open or private purchase$18.45$128,382.07
21st September 2020Partners L P/Il Bvf10,069Open or private purchase$18.39$185,119.57
Ideaya Biosciences
Ideaya Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


IDEA Biosciences, Inc. develops cancer therapeutics. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


Ticker: IDYA
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1676725
Employees: 47
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals